Latest news with #ContinuousGlucoseMonitors
India Today
25-04-2025
- Health
- India Today
Axiom-4 astronauts to test diabetes glucose monitor aboard Space Station
To enhance monitoring of glucose level, and diabetes in space, Axiom-4 astronauts will test Continuous Glucose Monitors (CGMs) during their mission aboard the International Space astronauts will launch on ISS aboard a SpaceX Dragon spacecraft piloted by Indian astronaut Shubhanshu Shukla in May 2025. The new CGMs have become the standard for glucose monitoring in individuals with diabetes on Earth and Burjeel Holdings, which develops the instrument now wants to test its efficiency in space so that they can be used on long-duration space The Suite Ride initiative involves flying and operating a suite of medical capabilities to further advancements in diabetes monitoring and treatment. Axiom Space's multi-tiered approach aims to eventually demonstrate that astronauts with insulin-dependent diabetes (IDDM) can be safely monitored, treated, and participate in off-planet Space has partnered with @BurjeelHoldings to test a suite of tools and technologies needed to support astronauts with insulin-dependent diabetes, enabling them to live and work in space. Learn more about the Suite Ride research that will be conducted during #Ax4: Axiom Space (@Axiom_Space) April 24, 2025Axiom Space said that comprehensive preflight, inflight, and post-flight protocols will employ various testing methods to validate these technologies. The Ax-4 mission also plans to look at insulin exposure in microgravity to assess the potency and stability of the drug product upon its return to technologies and advances that could result from this project could also improve our ability to provide remote care for patients with diabetes and other health conditions on Earth," Dr. Mike Harrison, chief medical officer at Axiom Space test is aimed at creating pathway for astronauts with IDDM to fly to space."The successful demonstration of glucose monitoring on subjects without diabetes will next open the door to flying astronauts with non-insulin-dependent Type 2 diabetes, looking to prove that people with diabetes can one day thrive in the unique environment of space," Axiom Space said in a In
Yahoo
19-03-2025
- Business
- Yahoo
Welldoc Achieves 50+ Patents, Unveiling "CGM-GPT" for Advanced Glucose Prediction
Digital Health Leader's Innovation in Real-Time Sensor-Based AI Sets New Standards for Personalized Cardiometabolic Care COLUMBIA, Md., March 19, 2025--(BUSINESS WIRE)--Welldoc®, a digital health leader revolutionizing cardiometabolic care, today announced the issuance of four new patents, marking its 54th patent grant. This milestone underscores Welldoc's relentless commitment to innovation and leadership in leveraging artificial intelligence (AI) and advanced predictive capabilities based on real-time sensor data. The company's digital health platform empowers individuals with personalized AI-driven digital coaching to enable self-management of cardiometabolic conditions, positive lifestyle changes and improved overall health and outcomes. The new patents focus on Welldoc's unique approach to combining dense, sensor-based data specifically collected from Continuous Glucose Monitors (CGM), with AI to predict future engagement levels, health metrics and improved outcomes. This includes the development of a "CGM-GPT" model using generative AI techniques to predict future glucose values. "Securing 50+ patents is a testament to the hard work of our talented team in the U.S. and India and their dedication to driving AI innovation in digital health," said Kevin McRaith, President and CEO of Welldoc. "We are proud to have built a strong foundation of intellectual property that enables us to deliver impactful cardiometabolic care solutions and drive continuous innovation in our product development. Protecting the underlying algorithms and functions that power the Welldoc platform is crucial to our ability to partner with healthcare industry leaders and create a more sophisticated, personalized experience for our users." Welldoc continues to expand its intellectual property portfolio, securing protections for a wide range of AI-driven and CGM-focused innovations. These include machine learning algorithms based on aggregated, complex health data—such as medications, symptoms and device data—and generative AI algorithms for curated content delivery along with first-in-class advanced capabilities in quantitative prediction, including weight and glucose levels. "It is well-known that generative, transformer-based AI models—most commonly known as large language models—may not work well for complex mathematical applications. They were designed to predict a series of words rather than numerical values," said Anand Iyer, PhD, MBA, Chief AI Officer of Welldoc. "We are creating our own specialized large sensor models, designed to tackle complex mathematical tasks, such as predicting future glucose levels, ultimately focused on advanced improvement to personalized health." Welldoc currently has patents granted and pending in the U.S. and globally, with plans to expand. About WelldocWelldoc®, a digital health leader revolutionizing cardiometabolic care, is integrating personalized, real-time and actionable insights into the daily lives of individuals living with cardiometabolic conditions, enabling improved health and outcomes. Welldoc's comprehensive digital health platform provides AI-powered digital coaching across pre-diabetes, diabetes, hypertension, heart failure and weight and obesity management, with integrated mental wellbeing and sleep support. Welldoc is an FDA-cleared digital health solution that guides individuals through the complicated journey of living with diabetes by enabling them to self-manage their care while enhancing connections to their healthcare team. The company partners with health plans, health systems and employers with the goal of extending care, improving health and reducing costs. Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform, and an IP portfolio of 50+ patents for its advanced AI and first-in-class tech. With over 90 clinical publications, Welldoc has also built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Welldoc is an industry thought leader and has been showcased in prestigious conferences and publications, including South by Southwest, The Wall Street Journal and The Economist. The company has been named the "Best Overall Digital Health Company" by MedTech Breakthrough for the past two years and was selected as a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit Follow us on LinkedIn and X. View source version on Contacts CTD CommsMegan Prock McGrath573-578-1184megan@
Yahoo
26-02-2025
- Health
- Yahoo
Why popular blood sugar monitors could actually be harming your health
Popular glucose monitors used to take regular blood sugar readings could be driving poor diets and food restrictions due to inaccurate measurements, according to a new study. Continuous Glucose Monitors (CGMs) take blood sugar readings every five minutes and were originally designed for people with diabetes to assess how their body responds to different foods. But they are growing in popularity and in recent years have increasingly been used by the health-conscious to track their diet and avoid glucose spikes. Now, research by University of Bath scientists in the American Journal of Clinical Nutrition suggests they may not be as accurate as once thought. The study warns that monitors may be overestimating blood sugar levels in healthy adults and prompting them to make unnecessary changes to their diet. Carried out in healthy, non-diabetic volunteers, the research compared results from a CGM to the gold standard finger-prick test for blood sugar levels. Scientists found that the CGMs consistently reported higher levels than the finger-prick test. The monitors overestimated the time spent above the Diabetes UK's recommended blood sugar level threshold by nearly 400 per cent, causing unnecessary concern for people whose blood sugar was actually well-controlled. Professor Javier Gonzalez, from the university's department of health, warned people should stick with the finger-prick test if they are looking for accurate readings. 'Continuous glucose monitors (CGMs) are fantastic tools for people with diabetes because even if a measurement isn't perfectly accurate, it's still better than not having a measurement at all,' he said. 'However, for someone with good glucose control, they can be misleading based on their current performance. 'For healthy individuals, relying on CGMs could lead to unnecessary food restrictions or poor dietary choices.' While CGMs were initially designed for those with diabetes, they have been increasingly used by other health conscious people simply to track their diet and avoid glucose spikes. After consuming a smoothie, one monitor showed a GI (Glycemic index) of 69, which is medium, while the finger-prick test showed a GI of 53, which is low. Whole fruits, which are classified as low-GI by finger prick tests, were classified as medium or high-GI foods by CGMs. Professor Gonzalez said CGMs may be inaccurate because they measure glucose in the fluid surrounding your cells, not directly in the blood. 'This can lead to discrepancies due to factors like time delays, blood flow, and how glucose moves between different parts of the body,' he said. Helen Whitby, company nutritionist at Innocent Drinks, which partly funded the research, said: "Smoothies and whole fruits are packed full of natural goodness and provide steady energy without sharp blood sugar spikes.'
The Independent
26-02-2025
- Health
- The Independent
Why popular blood sugar monitors could actually be harming your health
Popular glucose monitors used to take regular blood sugar readings could be driving poor diets and food restrictions due to inaccurate measurements, according to a new study. Continuous Glucose Monitors (CGMs) take blood sugar readings every five minutes and were originally designed for people with diabetes to assess how their body responds to different foods. But they are growing in popularity and in recent years have increasingly been used by the health-conscious to track their diet and avoid glucose spikes. Now, research by University of Bath scientists in the American Journal of Clinical Nutrition suggests they may not be as accurate as once thought. The study warns that monitors may be overestimating blood sugar levels in healthy adults and prompting them to make unnecessary changes to their diet. Carried out in healthy, non-diabetic volunteers, the research compared results from a CGM to the gold standard finger-prick test for blood sugar levels. Scientists found that the CGMs consistently reported higher levels than the finger-prick test. The monitors overestimated the time spent above the Diabetes UK's recommended blood sugar level threshold by nearly 400 per cent, causing unnecessary concern for people whose blood sugar was actually well-controlled. Professor Javier Gonzalez, from the university's department of health, warned people should stick with the finger-prick test if they are looking for accurate readings. 'Continuous glucose monitors (CGMs) are fantastic tools for people with diabetes because even if a measurement isn't perfectly accurate, it's still better than not having a measurement at all,' he said. 'However, for someone with good glucose control, they can be misleading based on their current performance. 'For healthy individuals, relying on CGMs could lead to unnecessary food restrictions or poor dietary choices.' While CGMs were initially designed for those with diabetes, they have been increasingly used by other health conscious people simply to track their diet and avoid glucose spikes. After consuming a smoothie, one monitor showed a GI (Glycemic index) of 69, which is medium, while the finger-prick test showed a GI of 53, which is low. Whole fruits, which are classified as low-GI by finger prick tests, were classified as medium or high-GI foods by CGMs. Professor Gonzalez said CGMs may be inaccurate because they measure glucose in the fluid surrounding your cells, not directly in the blood. 'This can lead to discrepancies due to factors like time delays, blood flow, and how glucose moves between different parts of the body,' he said. Helen Whitby, company nutritionist at Innocent Drinks, which partly funded the research, said: "Smoothies and whole fruits are packed full of natural goodness and provide steady energy without sharp blood sugar spikes.'
